Holen Sie sich die Stockscreener-App
21.89
4.34%
0.91
Schlusskurs vom Vortag:
$20.98
Offen:
$20.93
24-Stunden-Volumen:
1.63M
Relative Volume:
0.76
Marktkapitalisierung:
$3.66B
Einnahmen:
$890.53M
Nettoeinkommen (Verlust:
$30.57M
KGV:
121.61
EPS:
0.18
Netto-Cashflow:
$80.53M
1W Leistung:
+4.84%
1M Leistung:
+0.83%
6M Leistung:
+29.53%
1J Leistung:
+23.19%
1-Tages-Spanne:
$20.87
$21.92
1-Wochen-Bereich:
$20.84
$22.14
52-Wochen-Spanne:
$13.40
$25.23
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
Firmenname
Acadia Pharmaceuticals Inc
Sektor
Branche
Telefon
858-558-2871
Adresse
12830 EL CAMINO REAL, SAN DIEGO
Vergleichen Sie ACAD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACAD
Acadia Pharmaceuticals Inc
|
21.89 | 3.49B | 890.53M | 30.57M | 80.53M | 0.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.35 | 117.98B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
570.59 | 58.10B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
315.75 | 42.26B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
561.28 | 33.42B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
252.14 | 26.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-21 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Hold |
| 2025-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-08-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-27 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-03-12 | Herabstufung | Mizuho | Buy → Neutral |
| 2024-03-12 | Bestätigt | Needham | Buy |
| 2024-01-30 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-01-24 | Hochstufung | Needham | Hold → Buy |
| 2023-12-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-14 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-12-13 | Eingeleitet | Citigroup | Buy |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-11-06 | Hochstufung | Mizuho | Neutral → Buy |
| 2023-10-17 | Eingeleitet | UBS | Buy |
| 2023-10-10 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-01-03 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-11-04 | Herabstufung | Goldman | Neutral → Sell |
| 2022-11-01 | Eingeleitet | Loop Capital | Hold |
| 2022-08-08 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-08-05 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-06-21 | Herabstufung | Jefferies | Buy → Underperform |
| 2022-06-16 | Hochstufung | Jefferies | Hold → Buy |
| 2022-03-16 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2022-02-09 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2022-01-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-12-21 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-11-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-10-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Fortgesetzt | Needham | Hold |
| 2021-06-10 | Eingeleitet | Berenberg | Hold |
| 2021-04-07 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2021-04-06 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2021-04-06 | Herabstufung | Goldman | Buy → Neutral |
| 2021-04-06 | Herabstufung | Jefferies | Buy → Hold |
| 2021-04-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-05 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-03-10 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-03-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-03-09 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-03-09 | Bestätigt | H.C. Wainwright | Buy |
| 2021-03-09 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2021-03-09 | Herabstufung | Stifel | Buy → Hold |
| 2020-12-16 | Eingeleitet | Mizuho | Buy |
| 2020-11-16 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-08-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-07-07 | Hochstufung | Stifel | Hold → Buy |
| 2020-04-16 | Eingeleitet | Jefferies | Buy |
| 2020-03-31 | Hochstufung | Goldman | Neutral → Buy |
| 2020-03-06 | Eingeleitet | Citigroup | Buy |
| 2019-12-16 | Eingeleitet | Guggenheim | Buy |
| 2019-10-24 | Eingeleitet | Oppenheimer | Perform |
| 2019-10-01 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-09-13 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-10 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-07-23 | Bestätigt | Needham | Buy |
| 2018-12-10 | Eingeleitet | Canaccord Genuity | Hold |
| 2018-09-21 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2018-08-09 | Bestätigt | Stifel | Hold |
| 2018-08-07 | Eingeleitet | Stifel | Hold |
| 2018-08-06 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2017-10-06 | Fortgesetzt | Goldman | Neutral |
Alle ansehen
Acadia Pharmaceuticals Inc Aktie (ACAD) Neueste Nachrichten
The $12 Billion Opportunity Bolstering This Biotech Stock - Investor's Business Daily
ACADIA Pharmaceuticals’ SWOT analysis: stock poised for growth amid pipeline expansion - Investing.com
Acadia Pharmaceuticals Rides High On Patent Wins And Strong Pipeline - Finimize
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Acadia CEO sets sights on ‘much more assertive’ deals to invigorate pipeline - BioPharma Dive
ACAD: ACADIA Pharmaceuticals Receives Buy Rating from Needham | ACAD Stock News - GuruFocus
Acadia Pharmaceuticals Stock Price Undervalues Potential Market Opportunity of Nuplazid, Daybue, RBC Says - MarketScreener
Acadia Pharmaceuticals Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value Drivers - Yahoo Finance
ACADIA Pharmaceuticals (ACAD) Price Target Raised by RBC Capital | ACAD Stock News - GuruFocus
Acadia Pharmaceuticals (ACAD) Conducts Inducement Awards to Attract and Retain Top Talent - MSN
ACADIA Pharmaceuticals (NASDAQ:ACAD) shareholders have earned a 21% CAGR over the last three years - Yahoo Finance
Bavarian Nordic sells priority review voucher to US healthcare system USD 160m - medwatch.com
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ACAD Stock News - GuruFocus
Neuroscience Leader Acadia Pharmaceuticals Expands Team with 41 New Hires, Awards $4.1M in Stock Options - Stock Titan
Acadia wins patent appeal for key drug composition By Investing.com - Investing.com Nigeria
Safety scares and trial misses drag down neuro biotechs into Q2 - BioWorld MedTech
US appeals court confirms patent validity of Acadia's Parkinson's drug - MSN
Oral Proteins & Peptides Market worth US$24.00 billion by 2030 with 22.1% CAGR | MarketsandMarkets™METRO - METRO - NEWS CHANNEL NEBRASKA
Acadia Pharmaceuticals (ACAD) Secures Patent Win to Maintain Nup - GuruFocus
US Appeals Court Confirms Patent Validity of Acadia’s Parkinson’s Medication - Insider Monkey
Acadia wins patent appeal for key drug composition - Investing.com Australia
Acadia gets court approval related to Nuplazid patent - MSN
Fed Circ affirms rulings in Acadia’s fight against Parkinson’s drug copies - Life Sciences Intellectual Property Review
ACAD Patent Victory Secures Nuplazid Exclusivity Till 2030 | ACA - GuruFocus
US appeals court upholds Acadia’s patent for Parkinson’s drug in MSN Labs case - BusinessLine
Acadia secures NUPLAZID patent protection through 2030 By Investing.com - Investing.com South Africa
Acadia Win On Parkinson's Drug Patent Upheld By Fed. Circ. - Law360
Federal Court Upholds Acadia Pharmaceuticals (ACAD) Patent Victo - GuruFocus
Acadia Pharmaceuticals (ACAD) Secures Patent Victory - GuruFocus
Acadia Pharmaceuticals Again Prevails in Appeal Upholding Patent for Parkinson's Drug - marketscreener.com
Transcript : ACADIA Pharmaceuticals Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 04 - MarketScreener
US Appeals Court Confirms Patent Validity of Acadia's Parkinson's Drug - U.S. News & World Report
Acadia gets court approval related to Nuplazid patent (ACAD) - Seeking Alpha
Acadia Pharmaceuticals says Appeals Court confirms validity of NUPLAZID patent - TipRanks
Acadia secures NUPLAZID patent protection through 2030 - Investing.com
U.S. Court Of Appeals For The Federal Circuit Affirms Prior Delaware District Court Rulings In Favor Of Acadia In Nuplazid® (Pimavanserin) Composition Of Matter Patent - MarketScreener
Acadia Pharma (ACAD) announces affirmation from U.S. Court of Appeals in favor of Acadia in NUPLAZID patent - StreetInsider
U.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID® (pimavanserin) Composition of Matter Patent - Yahoo
JPMorgan Lifts Acadia Price Target After Nuplazid Patent Victory - Benzinga
JPMorgan Raises Acadia Pharmaceuticals (ACAD) Price Target to $3 - GuruFocus
JPMorgan raises Acadia Pharmaceuticals stock price target to $30 - Investing.com Australia
ACADIA Pharmaceuticals (ACAD) Receives Price Target Boost from J - GuruFocus
ACADIA Pharmaceuticals (ACAD) Receives Price Target Boost from JP Morgan | ACAD Stock News - GuruFocus
JPMorgan raises Acadia Pharmaceuticals stock price target to $30 By Investing.com - Investing.com Nigeria
Acadia Pharmaceuticals price target raised to $30 from $26 at JPMorgan - TipRanks
Finanzdaten der Acadia Pharmaceuticals Inc-Aktie (ACAD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.28%
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):